

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



July 13, 2023

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Scrip Name: SUNPHARMA

Scrip Code: 524715

Dear Sir / Madam,

Sub: Newspaper Advertisement – Notice for transfer of equity shares and unclaimed dividend to the Investor Education and Protection Fund (IEPF) Account

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed are the copies of newspaper advertisements published on July 13, 2023 regarding the notice for transfer of equity shares and unclaimed dividend to IEPF Account, requesting the concerned shareholders to take appropriate action to claim their dividend, which has not been paid or claimed by them for seven consecutive years or more, failing which their shares and unclaimed dividend will become liable to be transferred to the IEPF Account, in accordance with the Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary & Compliance Officer

ICSI Membership No.: A23983

Encl.: As above.

Markets end lower amid profit-taking after three-day rally


PRESS TRUST OF INDIA
Mumbai, July 12

BENCHMARK EQUITY INDICES ended lower on Wednesday after three days of gain amid profit-taking ahead of key macroeconomic data announcements as well as the first quarter earnings from TCS and HCL Technologies.

Fag-end selling pulled down the 30-share BSE Sensex lower, which declined 223.94 points or 0.34% to settle at 65,393.90. During the day, it hit a low of 65,320.25 and a high of 65,811.64. The NSE Nifty fell by 55.10 points or 0.28% to end at 19,384.30.

"Markets showed resilience in early trades, but the upward march had been showing signs of fatigue of late and investors today pulled the plug ahead of key domestic inflation data and

Sensex Intra-day July 12



the US CPI inflation... As the global economy remains under pressure, local markets are likely to witness bouts of profit-taking during such prolonged rallies," said Shrikant Chouhan, head of research (Retail), Kotak Securities. India's industrial production rose 5.2% in May, according to the official data released on Wednesday evening.

Sun Pharmaceutical Industries Limited
Regd. Office: SPARC, Tandajla, Vadodra - 390 012, Gujarat, India
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon - East, Mumbai - 400 063, Maharashtra, India
Tel: 022-43244324 CIN: L24206G1993PLC019050
Website: www.sunpharma.com Email: secretarial@sunpharma.com

NOTICE

Transfer of Equity Shares and unclaimed dividend to Investor Education and Protection Fund (IEPF) Account

This Notice is given pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs effective September 07, 2016 and as amended from time to time thereafter ("the Rules").

The Rules, amongst other matters, contain provisions for transfer of all shares, in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more, to the Investor Education and Protection Fund Account ("the IEPF Account").

Pursuant to the provisions set out in the Rules, the Company has communicated through individual notices, to the concerned shareholders whose shares are liable to be transferred to IEPF Account under the said Rules for taking appropriate action(s) to claim their unpaid dividend.

The Company has uploaded full details of such shares, which are due for transfer on 01 October 2023 to IEPF Account, on its website at <https://www.sunpharma.com/details-of-equity-shares-liable-for-transfer-to-iefp> and the shareholders are requested to verify the details of the shares liable to be transferred to IEPF Account.

The concerned shareholders, holding shares in physical form and whose shares are liable to be transferred to IEPF Account, may note that, as per the requirement of the Rules, the Company would be issuing new share certificate(s) for transfer of such shares to IEPF, in lieu of the original share certificate(s) which are registered in their names and these original share certificate(s) will stand automatically cancelled and be deemed non-negotiable. The shareholders may further note that the details uploaded by the Company on its website shall be regarded and shall be deemed to be adequate notice in respect of issue of the duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF Account pursuant to the Rules.

In case the shareholders do not receive any valid claim from the concerned shareholders by September 30, 2023, the Company, with a view to comply with the requirements set out in the Rules, shall transfer the corresponding shares and unclaimed dividend (declared by the Company on September 17, 2016) to the IEPF Account by the due dates as per procedure stipulated in the Rules. Please note that no claim shall lie against the Company in respect of unclaimed dividend and equity shares transferred to the IEPF Account/IEPF Authority.

Shareholders may note that both the unclaimed dividend and the shares transferred to IEPF Account/IEPF Authority including all the benefits accruing on such shares, if any, can be claimed back from IEPF Account/IEPF Authority, after following the procedure as prescribed under the Rules.

In case the shareholders have any queries on the subject matter, they may contact the Company's Registrar and Share Transfer Agent - Link Intime India Pvt. Ltd., C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai - 400 083, Tel No.: (022) 49186270, E-mail: rnt.helpdesk@linkintime.co.in

For Sun Pharmaceutical Industries Limited
Sd/-
Anoop Deshpande
Company Secretary and Compliance Officer
(Nodal Officer for the purpose of IEPF)

Place: Mumbai

Date: July 12, 2023

MORGAN VENTURES LIMITED

CIN: L70109DL1986PLC025841

Regd. Office: 37, Ring Road, Lajpat Nagar - IV, New Delhi 110024
Phone: 011-26432601/02/03, Email: secretarial@goyalgroup.com

NOTICE FOR 36TH ANNUAL GENERAL MEETING

Notice is hereby given that the 36th Annual General Meeting of the Company will be held on Saturday, August 05th, 2023 at 10:00 A.M. at 53, Friends Colony (East), New Delhi 110065.

The Annual Report of the Company for the year 2022-2023 including the financial statements for the year ended March 31, 2023 will be sent only by email to those Members, whose e-mail address were available with the Company's Registrar and Share Transfer Agent, Skyline Financial Services Private Limited and whose email addresses are registered with the Company or with their respective Depository Participants. The instructions for attending AGM and the manner of participation in the remote e-voting or casting vote during AGM are provided in the AGM Notice. The Notice of AGM and the Annual Report will also be available on the website of the Company i.e. www.morganventures.in and the website of Bombay Stock Exchange Limited i.e. www.bseindia.com.

Members holding shares in physical form who have not registered their e-mail addresses with the Company / Depositories can obtain Notice of the AGM, Annual Report and/or Login for e-voting facility, by sending email to secretarial@goyalgroup.com.

Pursuant to Section 91 of the Companies Act, 2013 read with Rule 10 of the Companies (Management and Administration) Rules, 2014 and Regulation 42 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, notice is further given that the Register of Members and Share Transfer Books will remain closed from Thursday, 27th July, 2023 to Friday, 04th August, 2023 for the purpose of Annual General Meeting.

In terms of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2013, as amended and Regulation 44 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company providing the facility to its Members to exercise their right to vote by electronic means on or any other businesses specified in the Notice convening the 36th AGM of the Company ("remote e-voting") through e-voting services of NSDL:

(a) The Company is providing remote e-voting facility to its Members to cast their vote by electronic means on the Resolutions set out in Notice in the Annual General Meeting dated 12th July, 2023.

(b) Day, Date and Time of Commencement of e-voting - Wednesday, 02nd August, 2023, 09.00 a.m.

(c) Day, Date and Time of ending of remote e-voting - Friday, 04th August, 2023, 05.00 p.m.

(d) Cut-off Date - 27th July, 2023.

(e) Any person who acquires shares of the Company and becomes a member of the Company after dispatch of the AGM Notice and holds shares as on the cut-off date i.e. 27th July, 2023 should follow the instructions for e-voting as mentioned in the AGM Notice which is available on the Company's website.

(f) Notice of AGM and Annual Report is available on Company's website and can be downloaded from www.morganventures.in

The Members are requested to note that

1. Remote e-voting module shall be disabled by NSDL for voting after Friday, 04th August, 2023, 05.00 p.m.

2. The facility for voting through ballot shall be made available at the venue of AGM.

3. The members who will be attending the meeting and who have not cast their votes through remote e-voting shall be able to exercise their voting rights through Ballot at AGM. The members who have already cast their vote through remote e-voting may attend the meeting but shall not be entitled to cast their vote again at the AGM.

4. Those members holding shares in physical form, whose email addresses are not registered with the Company may register their email address by communicating/writing to the Company's Registrar and Share Transfer Agent (RTA) Skyline Financial Services Pvt. Ltd., D-153A, 1st Floor, Phase I, Okhla Industrial Area, New Delhi 110020 at info@skylinetra.com along with the copy of the signed request letter mentioning the name and address of the shareholder, self attested copy of the PAN card and any other document (e.g. Driving licence, Election Identity Card, Passport) in support of the address of the Shareholder. The members who are holding shares in demat form, can update their email address with their respective Depository Participants.

5. Member holding share as on 27th July, 2023 shall only be entitled to avail the facility of remote e-voting or voting through ballot at the AGM.

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members available at the downloads section of www.evoting.nsdl.com or call on toll free no. 1800-222-990 or email- secretarial@goyalgroup.com

The results of the e-voting/voting at AGM ballot shall be declared on or before 5th August, 2023. The Results declared, along with the Scrutinizer's Report shall be placed on the Company's website and communicated to the Bombay Stock Exchange where the Company's shares are listed.

By Order of the Board of Directors
For Morgan Ventures Limited
Sd/- Kuldeep Kumar Dhar
Managing Director
DIN 00299386

Place: New Delhi

Date: 12.07.2023

Pharma index logs 16% gains in FY24

ASHLEY COUTINHO
Mumbai, July 12

AFTER MULTIPLE QUARTERS of lacklustre returns, the listed Indian pharma space has come back to life with the Nifty Pharma index gaining 16% in the current financial year, outperforming Nifty's 11.6% returns.

The recent rally has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with continued momentum in domestic branded formulations, according to experts. Stocks gaining the most during this period include Lupin (45.2%), Aurobindo Pharma (41.3%) and Torrent Pharma (25.2%).

Pharma funds have given average category returns of 15% in the past three months in absolute terms, according to Value Research, beating infrastructure, banking and technology sector funds and all other thematic funds.

Analysts expect pharma companies to report moderate growth in sales and sharp margin expansion in the first quarter of this financial year aided by improved US generics pricing and strength across most branded markets amid gradual easing of cost pressures.

"Pharma companies under our coverage are likely to report revenue, Ebitda and PAT

Performance of pharma stocks in FY24

Returns (%)



Source: Exchange

growth of 15%, 33% and 28% y-o-y in Q1 FY24E. The growth is likely to be led by new launches, market share expansion in key products and acquisition in US and India. Aggregate gross margin to improve marginally q-o-q at 64.8% as higher raw material cost and mandated price cut in India may offset the benefit of better margins, stated a recent note by ICICI Securities.

During FY22-23, the US generic pharma market witnessed unprecedented levels of price erosion in the wake of consolidation in buyer channels and decline in shortage opportunities.

"While over the last few months, the volume dynamics have remained unaltered, pricing pressures have begun to moderate. Despite a partial improvement in the trade terms over last year, generic

Vedanta bonds fall on exchange offer report

DIVYA PATIL &
SWANSY AFONSO
July 12

ALL THE FOUR outstanding dollar bonds of Vedanta Resources plunged Wednesday after report said banks have informally approached some investors for a potential exchange offer on some of the firm's notes.

On Monday, Foxconn decided to part ways with Vedanta on a planned semiconductor JV. Vedanta later said it remains committed to the chip project, raising concerns it may further stretch the company's finances. Foxconn, on the other hand, plans to apply for India government incentives for chip and display manufacturing and reviewing options for partners.

Vedanta Resources dollar bond due August 2024 fell 5.2 cents on the dollar to 65.5



■ Vedanta's dollar bond due August 2024 fell 5.2 cents on the dollar to 65.5 cents, the biggest drop since April 19

cents, the biggest drop since April 19, according to Bloomberg-compiled prices. The January 2024 notes lost 2.7 cents and April 2026 declined 4.7 cents. The mining giant's March 2025 notes lost 3.6 cents, also the most since March 20.

- BLOOMBERG

Outstanding vehicle loans rise 22% in May

VEHICLE LOANS OUTSTANDING increased by 22% year-on-year to ₹5.09 trillion in May, notwithstanding the Reserve Bank's rate hike spree in 2022-23.

As per the latest RBI data, the total vehicle loan outstanding climbed from ₹3.65 trillion in May 2021 to ₹4.16 trillion in May 2022, and further to ₹5.09 trillion as of May 19, 2023.

The annual rise in loan outstanding was only 14% in May 2022.

The RBI started raising the interest rate in May last year to check inflation in the wake of the Russia-Ukraine war and cumulatively increased the repo rate (benchmark interest rate) by 250 basis points in six tranches before pressing the pause button at the beginning of the current fiscal.

- PTI

Patanjali Ayurved to sell 7% stake in foods arm

BABA RAMDEV-LED PATANJALI Ayurved will sell up to 25.3 million shares in its group firm Patanjali Foods on stock exchanges in a bid to increase public float to meet listing requirements.

The shares of Patanjali Foods, which is into edible oil and other food products, will be floated through the Offer For Sale (OFS) route.

The floor price has been

fixed at ₹1,000 per equity share for the offer, which will be open on July 13 and 14, according to a regulatory filing by Patanjali Foods on Wednesday.

At the floor price, Patanjali Ayurved -- a promoter of Patanjali Foods -- will garner at least Rs 2,530 crore from the share sale. Shares of Patanjali Foods closed marginally higher at ₹1,228.05 apiece at BSE on Wednesday.

- PTI

Sebi notifies framework for ESG disclosures

PRESS TRUST OF INDIA
New Delhi, July 12

MARKETS WATCHDOG SEBI on Wednesday came out with a regulatory framework for listed entities on ESG (environment, social and governance) disclosures on supply chain and assurance.

In a bid to address the need for ESG disclosure assurance, Sebi has introduced BRSR Core, a subset of the BRSR (Business Responsibility and Sustainability Report), comprising nine Key Performance Indicators (KPIs) for several E, S and G factors that need to be assured.

Under the framework, large listed companies will have to make disclosures and obtain assurance as per 'BRSR Core' for their value chain.

Keeping in view the relevance to the Indian market context, few new KPIs have been identified for assurance such as job creation in small towns, openness of business and gross wages paid to

women.

Further, for better global comparability, intensity ratios based on revenue adjusted for purchasing power parity have been included.

In addition, Sebi has introduced disclosures and assurance for the value chain of listed entities, as per the BRSR Core.

In the supply chain, Sebi said that ESG disclosures according to the BRSR Core for the top 250 companies on a comply-or-explain basis will start from 2024-25, with assurance beginning the following year, according to a circular.

Disclosures for the value chain will be made by the listed company as per BRSR Core as part of its annual report.

In this regard, the value chain would encompass the top upstream and downstream partners of a listed entity, cumulatively comprising 75% of its purchases or sales by value, respectively.

PGIM India Asset Management Private Limited
4th Floor, C wing, Laxmi Towers, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.
Tel.: +91 22 6159 3000. Fax: +91 22 6159 3100
CIN: U74900MH2008FTC187029 Toll Free No.: 1800 266 7446
Website: www.pgimindiamf.com

NOTICE

Notice is hereby given that PGIM India Trustees Private Limited, Trustee to PGIM India Mutual Fund, has approved declaration of Income Distribution cum Capital Withdrawal (IDCW) under the following schemes of PGIM India Mutual Fund with **July 17, 2023** as the record date :-

Scheme Names	Plans / Options	Quantum of IDCW per Unit (Gross of Statutory Levy, if any)* (₹)	Face Value (₹ Per Unit)	NAV of IDCW Option as on July 11, 2023 (₹ per unit)#
PGIM India Arbitrage Fund	Regular Plan - Monthly IDCW Option	0.0402	10	10.7254
	Direct Plan - Monthly IDCW Option	0.0405	10	10.7996
PGIM India Hybrid Equity Fund	Regular Plan - Monthly IDCW Option	0.1600	10	22.6600
	Direct Plan - Monthly IDCW Option	0.1729	10	24.4900
PGIM India Equity Savings Fund	Regular Plan - Monthly IDCW Option	0.0716	10	12.6587
	Direct Plan - Monthly IDCW Option	0.0773	10	13.6727

*Pursuant to payment of IDCW, the NAV of the above-mentioned option of the Schemes would fall to the extent of payout and statutory levy, if any.

IDCW will be paid to those unit holders whose names appear in the records of the Registrar as at the close of business on the record date. For units in dematerialized form, all unit holders whose names appear in the beneficiary position file downloaded from the depositories as on the record date will be entitled to receive the IDCW.

*The IDCW distribution will be subject to the availability of distributable surplus under the schemes and may be lower to the extent of distributable surplus available on the Record Date.

For PGIM India Asset Management Private Limited
(Investment Manager for PGIM India Mutual Fund)

Place: Mumbai

Date: July 12, 2023

Sd/-
Authorized Signatory

Unit holders are requested to update their PAN, KYC, email address, mobile number, nominee details with AMC and are also advised to link their PAN with Aadhaar Number. Further, Unit holders can view the Investor Charter available on website of the Mutual Fund as well as check for any unclaimed redemptions or Income Distribution cum Capital Withdrawal (IDCW) payments.

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS,
READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**

For and on behalf of the Board
Sd/-
Ashok Kumar Dugar
Managing Director

12.07.2023
Kochi

18 MARKETS

Markets end lower amid profit-taking after three-day rally

PRESS TRUST OF INDIA
Mumbai, July 12



BENCHMARK EQUITY INDICES ended lower on Wednesday after three days of gain amid profit-taking ahead of key macroeconomic data announcements as well as the first quarter earnings from TCS and HCL Technologies.

Flag-end selling pulled down the 30-share BSE Sensex lower, which declined 223.94 points or 0.34% to settle at 65,393.90. During the day, it hit a low of 65,320.25 and a high of 65,811.64. The NSE Nifty fell by 55.10 points or 0.28% to end at 19,384.30.

"Markets showed resilience in early trades, but the upward march had been showing signs of fatigue of late and investors today pulled the plug ahead of key domestic inflation data and

the US CPI inflation... As the global economy remains under pressure, local markets are likely to witness bouts of profit-taking during such prolonged rallies," said Shrikant Chouhan, head of research (Retail), Kotak Securities. India's industrial production rose 5.2% in May, according to the official data released on Wednesday evening.

OUTPERFORMS NIFTY'S 11.6% RETURNS

Pharma index logs 16% gains in FY24

ASHLEY COUTINHO
Mumbai, July 12

AFTER MULTIPLE QUARTERS of lacklustre returns, the listed Indian pharma space has come back to life with the Nifty Pharma index gaining 16% in the current financial year, outperforming Nifty's 11.6% returns.

The recent rally has been driven by hospital and emerging green shoots in pharmaceutical exports, particularly to the US, along with continued momentum in domestic branded formulations, according to experts.

Stocks gaining the most during this period include Lupin (45.2%), Aurobindo Pharma (41.3%) and Torrent Pharma (25.2%).



The recent rally has been driven by hospital and emerging green shoots in pharmaceutical exports, particularly to the US, along with continued momentum in domestic branded formulations, according to experts.

Stocks gaining the most during this period include Lupin (45.2%), Aurobindo Pharma (41.3%) and Torrent Pharma (25.2%).

Pharma funds have given average category returns of 15% in the past three months in absolute terms, according to Value Research, beating infrastructure, banking and technology sector funds and all other thematic funds.

Analysts expect pharma companies to report moderate growth in sales and sharp margin expansion in the first quarter of this financial year aided by improved US generics pricing and strength across most branded markets amid gradual easing of cost pressures.

"Pharma companies under our coverage are likely to report revenue, Ebitda and PAT

growth of 15%, 33% and 28% y-o-y in Q1 FY24E. The growth is likely to be led by new launches, market share expansion in key products and acquisition in US and India. Aggregate gross margin to improve marginally q-o-q at 64.8% as higher raw material cost and mandated price cut in India may offset the benefit of better margins from niche US launches," stated a recent note by ICICI Securities.

During FY22-23, the US generic pharma market witnessed unprecedented levels of price erosion in the wake of consolidation in buyer channels and decline in shortage opportunities.

"While over the last few months, the volume dynamics have remained unaltered, pricing pressures have begun to moderate. Despite a partial improvement in the trade terms over last year, generic

pharma exports remain a commoditised space," a report by DAM Capital observed.

The brokerage believes that cost competitiveness is the key to survive and thrive in the business, and companies need to be willing to operate in high volume manufacturing model with a reasonable profitability. Generic players with a broad portfolio and significant vertical integration will be winners over the medium-to-long term, it said.

The brokerage further added that the complex generic space has failed to deliver in terms of revenues and profitability. This, coupled with the requirement of higher R&D spending for development of complex products, has led to a disappointing return on investment. On the other hand, the branded formulations space remains a high margin/ROCE and a sticky business with superior pricing power.

Vedanta bonds fall on exchange offer report

DIVYA PATIL & SWANSY AFONSO
July 12

ALL THE FOUR outstanding dollar bonds of Vedanta Resources plunged Wednesday after report said banks have informally approached some investors for a potential exchange offer on some of the firm's notes.

On Monday, Foxconn decided to part ways with Vedanta on a planned semiconductor JV. Vedanta later said it remains committed to the chip project, raising concerns it may further stretch the company's finances. Foxconn, on the other hand, plans to apply for India government incentives for chip and display manufacturing and reviewing options for partners.

Vedanta Resources dollar bond due August 2024 fell 5.2 cents on the dollar to 65.5



Vedanta's dollar bond due August 2024 fell 5.2 cents on the dollar to 65.5 cents, the biggest drop since April 19

cents, the biggest drop since April 19, according to Bloomberg-compiled prices. The January 2024 notes lost 2.7 cents and April 2026 declined 4.7 cents. The mining giant's March 2025 notes lost 3.6 cents, also the most since March 20.

- BLOOMBERG

Participatory notes' value at 5-year high of ₹1.04 trn

PRESS TRUST OF INDIA
New Delhi, July 12

FUELLED BY THE resilience of the Indian economy, investment in the domestic capital markets through participatory notes rose to ₹1.04 trillion in May-end, the highest level in over five years.

This includes the value of IPO note investments in Indian equity, debt, and hybrid securities.

Also, this marks the third consecutive monthly increase in the investment level through this route, data with the Securities and Exchange Board of India (Sebi) showed.

Participatory notes (P-notes) are issued by registered Foreign Portfolio Investors (FPIs) to overseas investors who wish to be part of the Indian stock market without registering themselves directly. They, however, need to go through a due diligence process.

According to Sebi data, the value of P-note investments in Indian markets -- equity, debt, and hybrid securities -- stood at ₹104,585 crore at the end of May, as compared to ₹95,911 crore in April-end.

In comparison, the investment through the route was ₹88,600 crore in March-end, ₹88,398 crore in February-end and ₹91,469 crore in January-end. The flow in the month of May was the highest level since March 2018, when investment through the route stood at ₹1.06 trillion.

Outstanding vehicle loans rise 22% in May

VEHICLE LOANS OUTSTANDING increased by 22% year-on-year to ₹5.09 trillion in May, notwithstanding the Reserve Bank's rate hike spree in 2022-23.

As per the latest RBI data, the total vehicle loan outstanding climbed from ₹3.65 trillion in May 2021 to ₹4.16 trillion in May 2022, and further to ₹5.09 trillion as of May 19, 2023.

The annual rise in loan outstanding was only 14% in May 2022.

The RBI started raising the interest rate in May last year to check inflation in the wake of the Russia-Ukraine war and cumulatively increased the repo rate (benchmark interest rate) by 250 basis points in six tranches before pressing the pause button at the beginning of the current fiscal.

- PTI

As per the latest RBI data, the total vehicle loan outstanding climbed from ₹3.65 trillion in May 2021 to ₹4.16 trillion in May 2022, and further to ₹5.09 trillion as of May 19, 2023.

Sun Pharmaceutical Industries Limited
Regd. Office: SPARC, Tandajai, Vadodra - 390 012, Gujarat, India
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon - East, Mumbai - 400 063, Maharashtra, India
Tel: 022-43244224 CIN: L24230G1993PLC019050
Website: www.sunpharma.com Email: secretarial@sunpharma.com

NOTICE

Transfer of Equity Shares and unclaimed dividend to Investor Education and Protection Fund (IEPF) Account

This Notice is given pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs effective September 07, 2016 and as amended from time to time thereafter ("the Rules").

The Rules, amongst other matters, contain provisions for transfer of all shares, in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more, to the Investor Education and Protection Fund Account ("the IEPF Account").

Pursuant to the provisions set out in the Rules, the Company has communicated through individual notice(s), to the concerned shareholders whose shares are liable to be transferred to IEPF Account under the said Rules for taking appropriate action(s) to claim their unpaid dividend.

The Company has uploaded full details of such shares, which are due for transfer on October 16, 2023 to IEPF Account, on its website at <https://www.sunpharma.com/details-of-equity-shares-liable-for-transfer-to-iefp> and the shareholders are requested to verify the details of the shares liable to be transferred to IEPF Account.

The concerned shareholders, holding shares in physical form and whose shares are liable to be transferred to IEPF Account, may note that, as per the requirement of the Rules, the Company would be issuing new share certificate(s) for transfer of such shares to IEPF, in lieu of the original share certificate(s) which are registered in their names and these original share certificate(s) will stand automatically cancelled and be deemed non-negotiable. The shareholders may further note that the details uploaded by the Company on its website shall be regarded and shall be deemed to be adequate notice in respect of issue of the duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF Account pursuant to the Rules.

In case the Company does not receive any valid claim from the concerned shareholders by September 30, 2023, the Company, with a view to comply with the requirements set out in the Rules, shall transfer the corresponding shares and unclaimed dividend (declared by the Company on September 17, 2016) to the IEPF Account by the due dates as per procedure stipulated in the Rules. Please note that no claim shall lie against the Company in respect of unclaimed dividend and equity shares transferred to the IEPF Account/IEPF Authority.

Shareholders may note that both the unclaimed dividend and the shares transferred to IEPF Account/IEPF Authority including all the benefits accruing on such shares, if any, can be claimed back from IEPF Account/IEPF Authority, after following the procedure as prescribed under the Rules.

In case the shareholders have any queries on the subject matter, they may contact the Company's Registrar and Share Transfer Agent - Link Intime India Pvt. Ltd., C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai - 400 083, Tel No.: (022) 49186270, E-mail: rnt.helpdesk@linkintime.co.in

For Sun Pharmaceutical Industries Limited
Sd/-
Anoop Deshpande
Company Secretary and Compliance Officer
(Nodal Officer for the purpose of IEPF)

Place: Mumbai
Date: July 12, 2023

HAILEYBURIA TEA ESTATES LTD.
Regd. Office : 24/432, Marar Road
Willingdon Island, Kochi - 682 003
CIN : L01132KL1923PLC000415, Phone : (0484) 2667653
E-mail : chinarteate@gmail.com
Website : www.chinnarteate.co.in

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023 (Rs. In Lacs)

Particulars	Quarter ended:		Year ended:	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations				
(a) Revenue from Operations	382.73	649.24	465.18	2,143.03
(b) Other Income	17.36	23.48	19.23	81.61
2 Total Income	400.09	672.72	484.41	2,224.64
3 Expenditure				
(a) Change in Inventories of Finished goods, stock-in-trade and work in progress	(300.39)	168.12	(167.03)	258.87
(b) Purchase of Stock-in-Trade	63.20	66.92	64.05	251.23
(c) Cost of raw material consumed	6.38	-	3.86	4.26
(d) Stores, Spares & packing materials Expenses	35.70	29.38	34.83	103.61
(e) Employee benefits Expenses	384.41	354.12	383.63	1,429.28
(f) Finance Costs	39.77	68.21	31.53	206.73
(g) Depreciation and amortisation expense	5.02	6.83	6.74	27.06
(h) Power, Fuel & Water Expenses	59.72	24.86	46.68	125.66
(i) Other Expenses	75.16	82.39	78.68	315.90
Total Expenses	368.97	800.83	482.97	2,722.60
4 Profit/(Loss) from operations before Exceptional Income (2-3)	31.12	(128.11)	1.43	(497.96)
5 Exceptional Item	-	113.19	-	113.19
6 Profit/(Loss) from operations before Tax (4-5)	31.12	(14.92)	1.43	(384.77)
7 Tax expense	-	-	-	-
8 Profit for the period (6-7)	31.12	(14.92)	1.43	(384.77)
9 Other Comprehensive Income				
A.(i) Items that will be Reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will not be Reclassified to Profit or Loss	-	(35.92)	-	(35.92)
B.(i) Items that will be Reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will be Reclassified to Profit or Loss	-	(35.92)	-	(35.92)
10 Total Comprehensive Income for the period (8+9)	31.12	(50.84)	1.43	(420.69)
11 Paid-up equity share capital (Face value/Share Rs.10/-)	157.50	157.50	157.50	157.50
12 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-
13 Earnings Per Share (EPS) - (not annualised) in Rs				
a) Basic and Diluted EPS before extraordinary items	1.98	(0.95)	0.09	(24.43)
b) Basic and Diluted EPS after extraordinary items	1.98	(0.95)	0.09	(24.43)
14 Public shareholding				
- Number of shares	4,02,432	4,02,432	4,02,432	4,02,432
- Percentage of shareholding	25.55%	25.55%	25.55%	25.55%
15 Promoters and Promoter Group Shareholding				
(a) Pledged / Encumbered				
- Number of Shares	Nil	Nil	Nil	Nil
- Percentage of Shares (as a % of the total shareholding of promoters and promoter group)	Nil	Nil	Nil	Nil
- Percentage of Shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
(b) Non-encumbered				
- Number of shares	11,72,568	11,72,568	11,72,568	11,72,568
- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100%	100%	100%	100%
- Percentage of Shares (as a % of the total share capital of the company)	74.45%	74.45%	74.45%	74.45%

BABA RAMDEV-LED PATANJALI Ayurved will sell up to 25.3 million shares in its group firm Patanjali Foods on stock exchanges in a bid to increase public float to meet listing requirements.

The shares of Patanjali Foods, which is into edible oil and other food products, will be floated through the Offer For Sale (OFS) route.

The floor price has been fixed at ₹1,000 per equity share for the offer, which will be open on July 13 and 14, according to a regulatory filing by Patanjali Foods on Wednesday.

At the floor price, Patanjali Ayurved -- a promoter of Patanjali Foods -- will garner at least Rs 2,530 crore from the share sale. Shares of Patanjali Foods closed marginally higher at ₹1,228.05 apiece at BSE on Wednesday.

- PTI

Patanjali Ayurved to sell 7% stake in foods arm

fixed at ₹1,000 per equity share for the offer, which will be open on July 13 and 14, according to a regulatory filing by Patanjali Foods on Wednesday.

At the floor price, Patanjali Ayurved -- a promoter of Patanjali Foods -- will garner at least Rs 2,530 crore from the share sale. Shares of Patanjali Foods closed marginally higher at ₹1,228.05 apiece at BSE on Wednesday.

- PTI

Sebi notifies framework for ESG disclosures

PRESS TRUST OF INDIA
New Delhi, July 12

MARKETSWATCHDOG SEBI on Wednesday came out with a regulatory framework for listed entities on ESG (environment, social and governance) disclosures on supply chain and assurance.

In a bid to address the need for ESG disclosure assurance, Sebi has introduced BRSR Core, a subset of the BRSR (Business Responsibility and Sustainability Report), comprising nine Key Performance Indicators (KPIs) for several E, S and G factors that need to be assured.

Under the framework, large listed companies will have to make disclosures and obtain assurance as per BRSR Core for their value chain.

Keeping in view the relevance to the Indian market context, few new KPIs have been identified for assurance such as job creation in small towns, openness of business and gross wages paid to

women.

Further, for better global comparability, intensity ratios based on revenue adjusted for purchasing power parity have been included.

In addition, Sebi has introduced disclosures and assurance for the value chain of listed entities, as per the BRSR Core.

In the supply chain, Sebi said that ESG disclosures according to the BRSR Core for the top 250 companies on a comply-or-explain basis will start from 2024-25, with assurance beginning the following year, according to a circular.

Disclosures for the value chain will be made by the listed company as per BRSR Core as part of its annual report.

In this regard, the value chain would encompass the top upstream and downstream partners of a listed entity, cumulatively comprising 75% of its purchases or sales by value, respectively.

MORGAN VENTURES LIMITED
CIN: L70109DL1986PLC025841

Regd. Office: 37, Ring Road, Lajpat Nagar - IV, New Delhi 110024
Phone: 011-26432601/02/03, Email: secretarial@goyalgroup.com

NOTICE FOR 36TH ANNUAL GENERAL MEETING

Notice is hereby given that the 36th Annual General Meeting of the Company will be held on Saturday, August 05th, 2023 at 10:00 A.M. at 53, Friends Colony (East), New Delhi 110065.

The Annual Report of the Company for the year 2022-2023 including the financial statements for the year ended March 31, 2023 will be sent only by email to those Members, whose e-mail address were available with the Company's Registrar and Share Transfer Agent, Skyline Financial Services Private Limited and whose email addresses are registered with the Company or with their respective Depository Participants. The instructions for attending AGM and the manner of participation in the remote e-voting or casting vote during AGM are provided in the AGM Notice. The Notice of AGM and the Annual Report will also be available on the website of the Company i.e. www.morganventures.in and the website of Bombay Stock Exchange Limited i.e. www.bseindia.com.

Members holding shares in physical form who have not registered their e-mail addresses with the Company / Depositories can obtain Notice of the AGM, Annual Report and/or Login for e-voting facility, by sending email to secretarial@goyalgroup.com.

Pursuant to Section 91 of the Companies Act, 2013 read with Rule 10 of the Companies (Management and Administration) Rules, 2014 and Regulation 42 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, notice is further given that the Register of Members and Share Transfer Books will remain closed from Thursday, 27th July, 2023 to Friday, 04th August, 2023 for the purpose of Annual General Meeting.

In terms of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2013, as amended and Regulation 44 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company providing the facility to its Members to exercise their right to vote by electronic means on any or all the businesses specified in the Notice convening the 36th AGM of the Company ("remote e-voting") through e-voting services of NSDL:

(a) The Company is providing remote e-voting facility to its Members to cast their vote by electronic means on the Resolutions set out in Notice in the Annual General Meeting dated 12th July, 2023.

(b) Day, Date and Time of Commencement of e-voting - Wednesday, 02nd August, 2023, 09:00 a.m.

(c) Day, Date and Time of ending of remote e-voting - Friday, 04th August, 2023, 05:00 p.m.

(d) Cut-off Date - 27th July, 2023.

(e) Any person who acquires shares of the Company and becomes a member of the Company after dispatch of the AGM Notice and holds shares as on the cut-off date i.e. 27th July, 2023 should follow the instructions for e-voting as mentioned in the AGM Notice which is available on the Company's website.

(f) Notice of AGM and Annual Report is available on Company's website and can be downloaded from www.morganventures.in

The Members are requested to note that:

1. Remote e-voting module shall be disabled by NSDL for voting after Friday, 04th August, 2023, 05:00 p.m.
2. The facility for voting through ballot shall be made available at the venue of AGM.
3. The members who will be attending the meeting and who have not cast their votes through remote e-voting shall be able to exercise their voting rights through Ballot at AGM. The members who have already cast their vote through remote e-voting may attend the meeting but shall not be entitled to cast their vote again at the AGM.
4. Those members holding shares in physical form, whose email addresses are not registered with the Company may register their email address by communicating/writing to the Company's Registrar & Share Transfer Agent (RTA) Skyline Financial Services Pvt. Ltd., D-153A, 1st Floor, Phase I, Okhla Industrial Area, New Delhi 110020 at info@skyline.in along with the copy of the signed request letter mentioning the name and address of the shareholder, self attested copy of the PAN card and any other document (e.g. Driving licence, Election Identity Card, Passport) in support of the address of the Shareholder. The members who are holding shares in demat form, can update their email address with their respective Depository Participants.
5. Member holding shares as on 27th July, 2023 shall only be entitled to avail the facility of remote e-voting or voting through ballot at the AGM.

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members available at the downloads section of www.evoting.nsdl.com or call on toll free no. 1800-222-990 or email-secretarial@goyalgroup.com

The results of the e-voting/voting at AGM ballot shall be declared on or before 5th August, 2023. The Results declared, along with the Scrutinizer's Report shall be placed on the Company's website and communicated to the Bombay Stock Exchange where the Company's shares are Listed.

By Order of the Board of Directors
For Morgan Ventures Limited
Sd/- Kuldeep Kumar Dhar
Managing Director
DIN 00299386

Place: New Delhi
Date: 12.07.2023

HAILEYBURIA TEA ESTATES LTD.
Regd. Office : 24/432, Marar Road
Willingdon Island, Kochi - 682 003
CIN : L01132KL1923PLC000415, Phone : (0484) 2667653
E-mail : chinarteate@gmail.com
Website : www.chinnarteate.co.in

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2023 (Rs. In Lacs)

Particulars	Quarter ended:		Year ended:	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations				
(a) Revenue from Operations	382.73	649.24	465.18	2,143.03
(b) Other Income	17.36	23.48	19.23	81.61
2 Total Income	400.09	672.72	484.41	2,224.64
3 Expenditure				
(a) Change in Inventories of Finished goods, stock-in-trade and work in progress	(300.39)	168.12	(167.03)	258.87
(b) Purchase of Stock-in-Trade	63.20	66.92	64.05	251.23
(c) Cost of raw material consumed	6.38	-	3.86	4.26
(d) Stores, Spares & packing materials Expenses	35.70	29.38	34.83	103.61
(e) Employee benefits Expenses	384.41	354.12	383.63	1,429.28
(f) Finance Costs	39.77	68.21	31.53	206.73
(g) Depreciation and amortisation expense	5.02	6.83	6.74	27.06
(h) Power, Fuel & Water Expenses	59.72	24.86	46.68	125.66
(i) Other Expenses	75.16	82.39	78.68	315.90
Total Expenses	368.97	800.83	482.97	2,722.60
4 Profit/(Loss) from operations before Exceptional Income (2-3)	31.12	(128.11)	1.43	(497.96)
5 Exceptional Item	-	113.19	-	113.19
6 Profit/(Loss) from operations before Tax (4-5)	31.12	(14.92)	1.43	(384.77)
7 Tax expense	-	-	-	-
8 Profit for the period (6-7)	31.12	(14.92)	1.43	(384.77)
9 Other Comprehensive Income				
A.(i) Items that will be Reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will not be Reclassified to Profit or Loss	-	(35.92)	-	(35.92)
B.(i) Items that will be Reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will be Reclassified to Profit or Loss	-	(35.92)	-	(35.92)
10 Total Comprehensive Income for the period (8+9)	31.12	(50.84)	1.43	(420.69)
11 Paid-up equity share capital (Face value/Share Rs.10/-)	157.50	157.50	157.50	157.50

